Showing results (21-30 of 33) with videos related to
Sort By:
Pageof 4
Hepatology (Baltimore, Md.)|July 19, 2012
Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trialSandra De Meyer, Inge Dierynck, Anne Ghys, et al.Journal of Virology|November 16, 2012
Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatmentDoug J Bartels, James C Sullivan, Eileen Z Zhang, et al.Plos Computational Biology|August 8, 2014
Modeling viral evolutionary dynamics after telaprevir-based treatmentEric L Haseltine, Sandra De Meyer, Inge Dierynck, et al.Journal of Virological Methods|March 31, 2015
A comparison of 454 sequencing and clonal sequencing for the characterization of hepatitis C virus NS3 variantsCynthia K Y Ho, Matthijs R A Welkers, Xiomara V Thomas, et al.Plos One|August 1, 2012
Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevirXiomara V Thomas, Joep de Bruijne, James C Sullivan, et al.Clinical and Translational Science|December 5, 2020
G970R-CFTR Mutation (c.2908G>C) Results Predominantly in a Splicing DefectMeredith C Fidler, Alexandra Buckley, James C Sullivan, et al.Antimicrobial Agents and Chemotherapy|July 2, 2014
Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitorMin Jiang, Eileen Z Zhang, Andrzej Ardzinski, et al.Hepatology (Baltimore, Md.)|May 10, 2014
Telaprevir-based treatment effects on hepatitis C virus in liver and bloodAndrew H Talal, Rositsa B Dimova, Eileen Z Zhang, et al.Annals of the American Thoracic Society|October 23, 2020
Ivacaftor in People with Cystic Fibrosis and a <i>3849+10kb C</i>→<i>T</i> or <i>D1152H</i> Residual Function MutationEitan Kerem, Malena Cohen-Cymberknoh, Reuven Tsabari, et al.Journal of Clinical Gastroenterology|May 16, 2014
Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicitySteven L Flamm, Andrew J Muir, Michael W Fried, et al.Pageof 4